Proactive Investors - Run By Investors For Investors

N4 Pharma surges on latest Nuvec study data

N4 Pharma has shown that Nuvec not only delivers DNA directly into cells, but that it does so to a sufficient level to generate an immune response
dna double helix
Nuvec delivers DNA directly into cells which encourages them to produce anti-cancer antigens

N4 Pharma PLC’s (LON:N4P) Nuvec delivery system has been shown to boost patients’ immune responses without the need for an additional adjuvant.

Nuvec works by delivering DNA directly into cells in a bid to encourage the production of anti-cancer antigens.

READ: EU innovation fund to cover some of Nuvec’s development costs

AIM-quoted N4 had thought any vaccine using the system might also need an adjuvant included in it to help stimulate an immune response.

But the research study showed that Nuvec had a “clear adjuvant effect” on its own, meaning an additional adjuvant would not be needed in vaccines using the delivery system.

N4 Pharma said this would simplify and reduce the production of the final vaccine and mean less antigen would be required.

Importantly, the immune response has been achieved using a dose of Nuvec particles that has shown no signs of liver toxicity, which is a common problem when using other delivery systems.

“We are pleased with the Nuvec results received to date and will continue to focus on the many opportunities that we believe will exist for Nuvec to be used to develop a range of different vaccines and cancer treatments,” said chief executive Nigel Theobald.

“We are building a compelling data package to aide our commercial collaboration discussions which we continue to progress.”

Shares were up 18.4% to 5.8p shortly before midday on Monday.

View full N4P profile View Profile

N4 Pharma PLC Timeline

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use